retatrutide

A 79-year-old patient with obesity, sleep apnea, and pulmonary hypertension received Eli Lilly's experimental drug retatrutide under a compassionate use program. The White House denied the drug was for President Trump after initial speculation.

Eli Lilly's obesity drug retatrutide is being made available to one individual through the FDA's 'compassionate use' program. The article discusses this development alongside broader questions about drugmaker acquisitions and the investment potential of hair loss drugs, as covered in a podcast episode.

The FDA analyzed its own data on youth tobacco use. The article highlights strong reporting by Lizzy on a patient who received retatrutide, though the focus remains on the FDA's delayed action regarding youth tobacco data.

The White House denied that Trump gained access to Eli Lilly's unapproved obesity drug retatrutide through a compassionate use program. The drug, not yet FDA approved, is available via a program that provides experimental treatments for life-threatening illnesses.

The White House denied a report suggesting President Trump received the investigational obesity drug retatrutide. STAT reported that Eli Lilly and the FDA approved a compassionate use request for the medication.

Eli Lilly and the FDA have allowed one person to receive the company's obesity drug retatrutide through the FDA's 'compassionate use' program. The access was granted via an exclusive report by Lizzy Lawrence.

Eli Lilly provided access to its experimental obesity drug retatrutide to a 79-year-old man through the FDA’s compassionate use program. The case drew interest from top health officials, suggesting the recipient was well connected.

Retatrutide, the most powerful weight-loss drug in development, is not expected to enter the U.S. market before next year but has already appeared on the black market.

Doctors are prescribing an experimental weight loss drug called retatrutide that has not been approved by the FDA, raising safety concerns. The treatment is currently under evaluation and not yet authorized for use.

The weight loss drug retatrutide, still in clinical trials and not FDA approved, is being prescribed by doctors despite potential serious side effects, according to a CBS News investigation. The drug has been described as 'Ozempic on steroids' and is being offered to patients before regulatory approval.

Eli Lilly's stock surged following record results from its next-generation weight loss drug, retatrutide. Participants on the highest dose lost an average of 28.3% of their body weight over 80 weeks.

Monotherapy with once-weekly retatrutide, an investigational triple hormone receptor agonist, improved glycemic control and body weight in adults with type 2 diabetes, as shown in the phase III TRANSCEND-T2D-1 trial. Up to 40% of patients achieved normal HbA1c levels.

A new triple-action weekly jab for type 2 diabetes, retatrutide, showed significant reductions in blood sugar and body weight in phase 3 trials. Patients receiving retatrutide lost over four times more weight and experienced more than twice the drop in HbA1c compared to placebo. The drug mimics three gut hormones (GLP-1, GIP, and glucagon) and differs from existing diabetes medications by engaging the glucagon receptor to increase energy expenditure.

Eli Lilly's next-generation obesity drug, retatrutide, demonstrated significant weight loss and blood sugar reduction in a study, but new data revealed seven cases of arrhythmias and three major cardiovascular complications among 403 participants. The findings were presented at the American Diabetes Association meeting and published in the Lancet.

New-generation GLP-1 drugs like retatrutide are achieving higher weight loss rates, raising questions about the safety and limits of rapid weight loss.

Eli Lilly announced clinical trial results for retatrutide, demonstrating that study participants lost an average of 70 lbs over 80 weeks. The drug shows greater efficacy than competing obesity medications Zepbound and Wegovy, positioning it as a more powerful next-generation treatment option.

A new weight-loss drug called Retatrutide is showing promising trial results that exceed the effectiveness of current weight-loss medications available on the market. Although not yet approved for public use, the drug demonstrates significantly stronger outcomes than existing options. Dr. Jon LaPook provides expert analysis on the drug's potential.

Eli Lilly's investigational obesity drug retatrutide met primary and key secondary endpoints in a phase 3 clinical trial, helping patients lose up to 30 percent of their body weight with a once-weekly injection. The highest dose achieved 28.3 percent weight loss, demonstrating clinically meaningful results.

Eli Lilly announced that its new weight-loss drug retatrutide significantly outperforms existing obesity medications, with trial participants losing an average of 28.3% of body weight over 80 weeks. The once-weekly injection led to 45.3% of participants achieving at least 30% weight loss, representing a major advancement in obesity treatment.

Eli Lilly's new weight loss drug retatrutide has shown remarkable trial results, potentially outperforming existing GLP-1 medications. The drug works by mimicking three hormones that regulate hunger and fat burning. NBC medical contributor Dr. Natalie Azar discusses the trial outcomes and FDA approval timeline.

Eli Lilly announces that its next-generation weight loss drug retatrutide has successfully passed a crucial obesity trial. The injection works through a different mechanism than existing weight loss treatments and brings the company closer to filing for regulatory approval.

Eli Lilly's obesity drug retatrutide demonstrated weight loss comparable to bariatric surgery in Phase 3 trials, with patients losing up to 28.3% of body weight after 80 weeks. However, the treatment showed concerning side effects with 11% discontinuation rates on the highest dose, significantly higher than competing drugs like Wegovy and Zepbound.

A new obesity treatment called retatrutide may help preserve muscle during weight loss by activating three hormones involved in regulating blood sugar, appetite and metabolism. Retatrutide is a triple agonist that has shown promising results in clinical trials with a lower side effect profile. It is administered as a once-weekly subcutaneous injection and can help people lose up to a third of their body weight.